MDKI inversione decennale


Le so tutte :-)
Punti reazioni
so che i volumi sono ridicoli pero'.......


  • chart.gif
    19,9 KB · Visite: 257
notate i volumi



  • mdki.gif
    13,2 KB · Visite: 175
almeno dimmi ke avevi accumulato!!!!:) :)
ne ho poche,

pero' ho la sensazione che questo sbotta,,,,,,,,,,,,

solo sensazione, ma vedendo i movimenti di alcuni titoli
poco liquidi in questi giorni, potrebbe esserci qualche sorpresa
no news

e' solo una sensazione percio' non comprate,,,,,,,,,

e' ancora buona,,,penso si possa salire

e' un po che la tengo sott'occhio,,,
anche con questo strappo,,
penso che i conti siano a posto,,

fondamentali piuttosto ragionevoli,,
fossi in te anziche vendere incrementerei,,,

credo che possa arrivare a 5-6$ tranquillamente,,,
sempre che non ci siano cattive sorprese,,


:eek: :eek: :eek:


  • mdki.gif
    12,6 KB · Visite: 126
CharlesIngalls ha scritto:
Ciao miris... mi guardi TFCT ? ;)

non trovo dati,,,,,,,,,,,,,,,,

solo vendite da insiders,,,,,
grande MIRIS :bow: :bow: :bow: :bow: :bow: :bow: :bow: :bow:
nn ti voto xchè mi sa che nn gradisci.... :D
oggi aprirà con un bel gup up, in pre siamo a 13.55 contro una chiusura ieri a 9.27
PRESS RELEASE: Dialysis Corporation of America to Acquire Medicore, Inc. [DYKSMBP]

Dialysis Corporation of America to Acquire Medicore, Inc.

LINTHICUM, Md. and HIALEAH, Fla., March 15, 2005 (PRIMEZONE) -- Dialysis
Corporation of America (NASDAQ:DCAI) and Medicore, Inc. (NASDAQ:MDKI) jointly
announced that they have agreed to terms whereby Medicore, Inc., which owns 57%
of Dialysis Corporation of America ("DCA"), will merge into DCA for a total
consideration of approximately 5,289,000 shares of DCA common stock. Upon
completion of the merger, each Medicore shareholder will receive .68 shares of
DCA common stock for each share of Medicore common stock, Medicore's current 57%
ownership of DCA will be retired, and the aggregate outstanding shares of DCA
will be approximately 9,000,000 shares of common stock.

The merger will simplify the corporate structure and enable the ownership of
the control interest of DCA to be in the public hands, rather than one
controlling party. This merger will also provide DCA with the assets of Medicore
to continue to build its dialysis business, and create the opportunity to expand
the medical supply operations.

DCA President & CEO, Stephen Everett, commented, "The infusion of additional
capital resources into our company makes this very appealing to DCA as we
continue to build and expand our company."

Thomas K. Langbein, President & CEO of Medicore, and Chairman of both
companies, added, "Medicore has been more than pleased with the growth and
success that DCA has demonstrated, and we look forward to the future of DCA."

The boards of each of DCA and Medicore approved the merger of the two
companies. Completion of the transaction is subject to, among other things,
customary closing conditions, satisfactory tax and fairness opinions, and the
approval by the shareholders of each company, which approvals will be sought at
the annual meetings of each of those companies, currently anticipated to take
place in July, 2005. No DCA stock consideration will be issued in this
transaction until the merger is consummated following approval by the
stockholders of both companies.

DCA owns and operates freestanding kidney hemodialysis centers located in
Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina and Virginia,
and provides in-hospital dialysis services on a contract basis to certain
hospitals located in those states. DCA provides patients with their choice of a
full range of quality in-center, acute or at-home hemodialysis services.

Medicore is primarily engaged in the operation of kidney dialysis centers
through DCA, and also has a medical supply division which distributes medical
products, owns realty in Hialeah, Florida, and holds investments in two
affiliated Linux software companies.

DCA will file a registration statement, which will include a proxy
statement/prospectus as well as other the relevant documents concerning the
proposed transaction. Stockholders are urged to read the proxy
statement/prospectus when it becomes available and all other relevant documents
filed with the SEC, as well as amendments or supplements to those documents, as
they will contain important information as to DCA and Medicore, the proposed
transaction, and the stockholder approval process.

You will be able to obtain a free copy of the proxy statement/prospectus, as
well as other filings containing important information about DCA and Medicore,
at the SEC's internet site, Copies of the proxy
statement/prospectus can be obtained without charge, by directing a request to
Lawrence E. Jaffe, Secretary of Medicore and DCA, at Jaffe & Falk, LLC, 777
Terrace Avenue, Hasbrouck Heights, NJ 07604, telephone: (201) 288-8282.

Medicore and its respective directors and executive officers may be deemed to
be participants in the solicitation of proxies from the stockholders of Medicore
in connection with the proposed merger. The proxy statement/prospectus will
include DCA's information statement, and does not require a solicitation of
proxies from DCA stockholders. Information about the executive officers and
directors of Medicore and DCA and their respective ownership of Medicore and DCA
common stock will be set forth in the proxy statement/prospectus, which will
update the information provided in the Medicore proxy statement dated April 27,
2004 for Medicore's 2004 annual meeting of stockholders, and DCA's information
statement dated April 27, 2004 for DCA's 2004 annual meeting, each as filed with
the SEC. Information regarding the interests of directors and executive officers
of Medicore and DCA in the merger and related transactions will be included in
the proxy statement/prospectus and other relevant documents to be filed with the

This release contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results and plans to differ materially
from those anticipated. Those factors include, but are not limited to, receipt
of satisfactory tax and fairness opinions and shareholder approval as indicated
above, the declaration of effectiveness by the SEC of a registration statement
to be filed covering DCA's common stock consideration to the Medicore
shareholders, which review and effectiveness process provides uncertainties as
to the timing of the meetings for shareholder approval. In addition, there may
be certain delays beyond DCA's control with respect to future business events,
the highly competitive environment in the establishment and operation of
dialysis centers, the ability to develop or acquire additional dialysis
facilities, whether patient bases of DCA's facilities can expand to provide
profitability, regulation of dialysis operations, government rate determination
for Medicare reimbursement, and other risks detailed in DCA's filings with the
SEC, particularly as described in DCA's annual report on Form 10-K for the
fiscal year ended December 31, 2003, and those to be set forth in its annual
report on Form 10-K for the fiscal year ended December 31, 2004, to be filed on
or about March 31, 2005. Other DCA press releases, corporate profile, corporate
governance materials, quarterly and current reports, and other filings with the
SEC are available on DCA's internet home page:

Medicore has similar risks and uncertainties, and in addition to those
reflected for DCA, has the risk as to the value it may realize on its ownership
interest in two affiliated Linux software companies. Other risks are detailed in
Medicore's filings with the SEC, particularly as described in its annual report
on Form 10-K for the year ended December 31, 2003, and those set forth in its
annual report on Form 10-K for the fiscal year ended December 31, 2004, to be
filed on or prior to March 31, 2005. Medicore's press releases, corporate
profile, corporate governance materials, and other reports and filings with the
SEC are available on Medicore's internet home page:

CONTACT: Dialysis Corporation of America

Stephen W. Everett, President & CEO

(410) 694-0500

Medicore, Inc.

Thomas K. Langbein, Chairman of the Board, President & CEO

(201) 288-8220

(END) Dow Jones Newswires
15-03-05 1247GMT(AP-DJ-03-15-05 1247GMT)

(C) Dow Jones & Company, Inc. All rights reserved.
15mar05 12:47 GMT